Novo Nordisk A/S Continues Its Comeback
Novo Nordisk (NYSE: NVO) released earnings for the first half of 2017, and while revenue growth wasn't spectacular, considering how last year went for the diabetes specialist, investors will take it.
Metric
H1 2017
Source: Fool.com
Sanofi S.A. ADR Aktie
45,40 €
-0,44 %